Drug Interaction Report

ADJUST DOSING INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of rosuvastatin. The mechanism of interaction has not been established but may involve a pH-dependent reduction in drug dissolution and absorption. According to the manufacturer, a decrease in rosuvastatin plasma concentration of approximately 50% was observed during simultaneous dosing with an antacid suspension containing aluminum and magnesium hydroxide. The effect was mitigated when the antacid was given two hours after the rosuvastatin dose. The clinical significance of this interaction is unknown.

MANAGEMENT: Until further data are available, patients treated with rosuvastatin should probably avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of rosuvastatin.

ADJUST DOSING INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of rosuvastatin. The mechanism of interaction has not been established but may involve a pH-dependent reduction in drug dissolution and absorption. According to the manufacturer, a decrease in rosuvastatin plasma concentration of approximately 50% was observed during simultaneous dosing with an antacid suspension containing aluminum and magnesium hydroxide. The effect was mitigated when the antacid was given two hours after the rosuvastatin dose. The clinical significance of this interaction is unknown.

MANAGEMENT: Until further data are available, patients treated with rosuvastatin should probably avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of rosuvastatin.